Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pulmonx Corporation (LUNG:NASDAQ), powered by AI.
Pulmonx Corporation is currently trading at $1.25. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Pulmonx Corporation on Alpha Lenz.
Pulmonx Corporation's P/E ratio is -0.9.
“Pulmonx Corporation trades at a P/E of -0.9 (undervalued) with modest ROE of -77.2%. 3Y revenue CAGR of 19.0% highlights clear growth momentum.”
Ask for details →Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.
“Pulmonx Corporation trades at a P/E of -0.9 (undervalued) with modest ROE of -77.2%. 3Y revenue CAGR of 19.0% highlights clear growth momentum.”
Ask for details →Pulmonx Corporation (ticker: LUNG) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 7,859 employees. Market cap is $51M.
The current price is $1.25 with a P/E ratio of -0.94x and P/B of 0.94x.
ROE is -77.19% and operating margin is -59.30%. Annual revenue is $90M.